...
机译:用R-Chec治疗弥漫性大B细胞淋巴瘤MYD88 L265P突变的高频和预后值
Univ Elect Sci &
Technol China Sch Med Sichuan Canc Ctr Sichuan Canc Hosp &
Inst Dept Med Oncol;
Univ Elect Sci &
Technol China Sch Med Sichuan Canc Ctr Sichuan Canc Hosp &
Inst Dept Clin Lab;
Univ Texas Hlth Sci Ctr Houston Dept Biostat Houston TX 77030 USA;
Univ Texas Hlth Sci Ctr Houston McGovern Med Sch Houston TX 77030 USA;
Univ Elect Sci &
Technol China Sch Med Sichuan Canc Ctr Sichuan Canc Hosp &
Inst Dept Clin Lab;
Univ Elect Sci &
Technol China Sch Med Sichuan Canc Ctr Sichuan Canc Hosp &
Inst Dept Med Oncol;
Univ Elect Sci &
Technol China Sch Med Sichuan Canc Ctr Sichuan Canc Hosp &
Inst Dept Biochem &
Univ Elect Sci &
Technol China Sch Med Sichuan Canc Ctr Sichuan Canc Hosp &
Inst Dept Med Oncol;
myeloid differentiation factor 88 L265P; diffuse large B-cell lymphoma; rituximab plus cyclophosphamide; doxorubicin; vincristine; prednisone; allele-specific semi-nested polymerase chain reaction;
机译:用R-Chec治疗弥漫性大B细胞淋巴瘤MYD88 L265P突变的高频和预后值
机译:形态学模式及其与MyD88 L265P的相关性,原发性肾上腺弥漫性大B细胞淋巴瘤中的CD79B突变
机译:原发性乳腺弥漫性大B细胞淋巴瘤中MYD88 L265P和CD79B的频繁突变
机译:弥漫性大B细胞淋巴瘤与中枢神经系统复发的突变特征:用于癌症基因组学数据库的CBioPortal分析
机译:利妥昔单抗时代的原发性胃弥漫性大B细胞淋巴瘤的预后模型,包括肿瘤细胞的EBV状态
机译:R-CHOP治疗MYD88 L265P突变在弥漫性大B细胞淋巴瘤中的高频率和预后价值
机译:MyD88 L265P突变和CDKN2A损失是亚型中枢神经系统的早期突变事件弥漫性大B细胞淋巴瘤